Simavita Limited
ASX : SVA
TSX VENTURE : SV

Simavita Limited

July 25, 2016 08:00 ET

Simavita Limited Voluntarily Delists From the Canadian TSX Venture Exchange

Trading to Continue on the Australian Securities Exchange

SYDNEY, AUSTRALIA--(Marketwired - July 25, 2016) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV)(ASX:SVA) advises that it has received notice from the TSX Venture Exchange (the "TSX-V") that the Company's securities will be delisted from the TSX-V effective at the close of business on August 3, 2016 and therefore will no longer be traded on the TSX-V after that date.

Importantly, investors should note that, the Company's common shares will continue to trade on the Australian Securities Exchange (the "ASX") under the ASX Code "SVA".

The Company applied to voluntarily delist from the TSX-V due to the following factors:

  • A restructuring of the Company's operations in line with Simavita's goal to materially decrease costs;
  • Minimal transaction volume associated with share movements on the TSX-V;
  • The vast majority of the Company's investors are Australian based. Accordingly, a single listing for the Company on the Australian stock market will better serve investors and investment in the Company.

Due to the potential cost associated with changing the Company's domicile, Simavita will continue to maintain a Canadian holding company. Accordingly, Simavita shares will be traded on the ASX as CHESS Depositary Interests or "CDIs" for the time being.

Implications for holders on the Company's Canadian register

Shareholders who are registered on the Canadian register will shortly receive a letter in relation to the delisting process after its securities have been delisted from the TSX-V.

In order to trade their shares on the ASX, shareholders on the Company's Canadian register will need to transfer their holdings to the Company's Australian register by completing and submitting the "Register Removal request - Canada to Australia CDIs" request form. The applicable form can be obtained from the Company's Canadian share registry, Computershare Investor Services Inc. ("Computershare") by either:

  1. downloading a form at: http://www.simavita.com/irm/company/showpage.aspx/PDFs/1209-14109281/CDIIssuanceCanadianRegistertoAustralianCDIRegister;

    or
  1. contacting Computershare's Global Transaction Unit on:
  • Canada (toll free) at 866-277-2086;
  • US (toll free) at 877-624-5999; or
  • International +1-781-575-4086

For shareholders who hold their shares through a broker or other intermediary which is a CDS participant, the CDS participant/broker must complete and submit the "CDI Issuance Form", or submit the CDI Issuance Instructions through xSettle on the shareholders behalf.

Until a transfer to the Australian register is effected, shareholders on the Company's Canadian register and beneficial shareholders holding their securities through a CDS participant broker will not be able to trade their shares on the ASX and their holdings will remain on the Canadian share register.

Shares held on the Canadian register which have not been transferred by December 6, 2016 will automatically be transferred to an Issuer Sponsored Holding on the Australian share register and all share certificates previously issued by Computershare Canada will become invalid following the issue by the Australian share register of an Issuer Sponsored Holding Statement.

For further information in relation to the transfer process, please contact Computershare's Global Transaction Unit (refer details above) or the Company Secretary on +61 421 466 653.

About Simavita

Simavita is a company established to deliver innovative continence solutions for our customers developed in ethical collaboration with healthcare professionals.

Simavita's patented and leading diagnostic tool is designed to dramatically improve the quality of life for those suffering from incontinence. For operators, hospitals and rehabilitation centres, this enables care providers and other institutions to significantly lower their material costs and reduce the time required to manage incontinence in patients.

Operating in Australia, Europe and North America, conducting assessments is mandatory in these countries and the incontinence assessment creates an influential element of care of each individual.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Simavita Limited
    +61 421 466 653